Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
Cheng-Chun Ji, Shota Takano
Intest Res. 2017;15(2):182-186.   Published online 2017 Apr 27     DOI: https://doi.org/10.5217/ir.2017.15.2.182
Citations to this article as recorded by Crossref logo
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92.     CrossRef
Predictors of reoperation for perianal fistula in Crohn's disease
Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
Journal of Digestive Diseases.2021; 22(6): 334.     CrossRef
Managing Complex Perianal Fistulizing Disease
Karina E. Pedersen, Amy L. Lightner
Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 890.     CrossRef
Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn’s disease treated with antitumor necrosis factor-alpha agents based on Parks’ classification
Nahla Azzam, Othman Alharbi, Majid Almadi, Abdulrahman Aljebreen, Turki AlAmeel, Mohammed Alabbas, Salman Bahammam, Ahmed Bashmail, Yasser Alomar, Mahmoud Mosli
European Journal of Gastroenterology & Hepatology.2020; 32(2): 187.     CrossRef
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29.     CrossRef
Characteristics of biological therapy in pediatric patients with Crohn’s disease
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
Expert Opinion on Biological Therapy.2019; 19(3): 181.     CrossRef
Endorectal Advancement Flaps for Perianal Fistulae in Crohn’s Disease: Careful Patient Selection Leads to Optimal Outcomes
Michelle T. Roper, Stephen M. Trinidad, Sonia L. Ramamoorthy, Lisa A. Parry, Nicole E. Lopez, Sergey Khaitov, Randolph Steinhagen, Samuel G. Eisenstein
Journal of Gastrointestinal Surgery.2019; 23(11): 2277.     CrossRef
Maneuvering Clinical Pathways for Crohn’s Disease
Thomas X. Lu, Russell D. Cohen
Current Gastroenterology Reports.2019;[Epub]     CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Journal of Gastroenterology and Hepatology.2019; 34(8): 1296.     CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Intestinal Research.2019; 17(3): 285.     CrossRef
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Jong Pil Im
Intestinal Research.2017; 15(2): 147.     CrossRef